



Trevena, Inc. (Nasdaq: TRVN) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, Oct. 27, 2015 (GLOBE NEWSWIRE) --

What:

Trevena, Inc. (Nasdaq:TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), will visit the Nasdaq MarketSite in Times Square in celebration of its recent positive Phase 2 data and successful secondary offering. The visit will also celebrate Trevena's Analyst and Investor Day, which is taking place on October 28th in New York City.

In honor of the occasion, **Dr. Maxine Gowen, President & Chief Executive Officer** will ring the Closing Bell.

Where:

Nasdaq MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio

When:

Wednesday, October 28, 2015 - 3:45 p.m. to 4:00 p.m. ET

Trevena, Inc. Media Contact:

Argot Partners
Eliza Schleifstein
(917) 763-8106
eliza@argotpartners.com

Nasdaq MarketSite:

William Briganti
(646) 441-5012
william.briganti@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: <http://www.facebook.com/NASDAQ>.

For photos from ceremonies and events visit our Instagram Page:
<http://instagram.com/nasdaq>

For news tweets, please visit our Twitter page at:
<http://twitter.com/nasdaq>

For exciting viral content and ceremony photos visit Tumblr Page:
<http://nasdaq.tumblr.com/>

Webcast:

A webcast of the Nasdaq Closing Bell will be available at:
<https://new.livestream.com/nasdaq/live> or <http://www.nasdaq.com/about/marketsitetowervideo.aspx>

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Trevena, Inc. (Nasdaq:TRVN):

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified - TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (completed Phase 2), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for acute episodic migraine and other CNS disorders (preclinical).

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately \$8.8 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-

 Primary Logo

Source: NASDAQ, Inc.

News Provided by Acquire Media